Regeneron Pharmaceuticals Inc
NASDAQ: REGN
$782.51
-$21.82 (-2.7%)
Closing Price on November 14, 2024
REGN Articles
24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a big push as 2020 continues.
Published:
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Published:
Brokerage firm Canaccord Genuity issued some key takeaways on a few different companies at ASCO. 24/7 Wall St. has also included some recent data on the stock.
Published:
Intellia Therapeutics shares rallied after it announced an expansion to its collaboration with Regeneron Pharmaceuticals.
Published:
Tuesday's top analyst upgrades and downgrades included Chembio Diagnostics, Cognex, Cree, Deere, Gilead Sciences, Halliburton, iRobot, Lam Research, Nvidia, Regeneron Pharmaceuticals, Sorrento...
Published:
Last Updated:
These are five of the best stocks in a sector that has been humming along in what has been a turbulent year. They are all included on the Goldman Sachs Conviction List too.
Published:
Regeneron Pharmaceuticals reported its first-quarter financial results before the markets opened on Tuesday. While the earnings were important, and fairly positive, more investors seemed interested...
Published:
Tuesday's top analyst upgrades and downgrades included AT&T, Cognex, Johnson & Johnson, Keurig Dr Pepper, PayPal, Roku, Shopify, Square, Valero Energy and Walt Disney.
Published:
Friday's top analyst upgrades and downgrades included CBOE, Citrix Systems, Etsy, Intercontinental Exchange, Lululemon Athletica, Microsoft, Peloton Interactive, Regeneron Pharmaceuticals, Twitter...
Published:
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
Published:
U.S. consumer confidence continues to decline, but the slide has slowed. On Sunday, the FDA and the Department of Health and Human Services okayed two drugs for use in the fight against COVID-19.
Published:
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this coronavirus and here is where their stocks stand now.
Published:
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this novel coronavirus. Here's how they fared as the week wound down.
Published:
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
Published:
Thursday's top analyst upgrades, downgrades and initiations included Akamai Technologies, Anheuser-Busch InBev, Boeing, BP, Comcast, Duke Energy, Gap, Kinder Morgan, Lyft, Occidental Petroleum, Snap,...
Published: